{"product_id":"umbilical-cord-blood-banking-and-transplantation","title":"Umbilical Cord Blood Banking and Transplantation","description":"\u003cp id=\"__p2\" class=\"p p-first\" data-mce-fragment=\"1\"\u003eMy interest in blood stem cells and cord blood dates back to my fellowship in Pediatric Hematology\/Oncology at Duke. During my fellowship, I worked on the development of novel antileukemia drugs based on analogs of purine metabolism and treated a teenage patient with refractory T‐cell acute lymphoblastic leukemia with a novel anti‐leukemia drug, 2′‐deoxycoformycin, an inhibiter of adenosine deaminase. During 5‐day course of therapy, his leukemia converted from a T‐lymphoid to a myeloid phenotype before our eyes\u003cspan data-mce-fragment=\"1\"\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5442723\/#sct312161-bib-0001\" class=\"ref\" data-mce-fragment=\"1\" data-mce-href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5442723\/#sct312161-bib-0001\" rid=\"sct312161-bib-0001\"\u003e1\u003c\/a\u003e. I subsequently established a cell line from these leukemic cells, DU‐528 and, ultimately, proved that this leukemia arose from a common lymphoid‐myeloid progenitor cell\u003cspan data-mce-fragment=\"1\"\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5442723\/#sct312161-bib-0002\" class=\"ref\" data-mce-fragment=\"1\" data-mce-href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5442723\/#sct312161-bib-0002\" rid=\"sct312161-bib-0002\"\u003e2\u003c\/a\u003e, which then led me to the study of hematopoietic stem and progenitor cells. Hal Broxmeyer, who would go on to become a pioneer in the use of cord blood as a source of donor cells for bone marrow reconstitution, mentored me as I studied normal and malignant hematopoietic stem cells isolated from bone marrow, fetal liver, and umbilical cord blood. In the clinic, I cared for children with leukemias and blood dyscrasias, including a young boy named Matthew Farrow from Salisbury, NC, with Fanconi anemia (FA) and evolving bone marrow failure. This genetic disease, which arises from a mutation in genes that encode the enzymes responsible for DNA repair, is associated with a host of serious medical and developmental problems. The prognosis for Matthew's condition was stark: most children with Fanconi anemia died of bone marrow failure or leukemia in the first decade of life, unless treated with a bone marrow transplant from a human leukocyte antigen (HLA)‐matched donor.\u003c\/p\u003e","brand":"Books Baar","offers":[{"title":"Default Title","offer_id":46278628573443,"sku":null,"price":1900.0,"currency_code":"PKR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0696\/9324\/3651\/files\/UmbilicalCordBloodBankingandTransplantation.jpg?v=1735852849","url":"https:\/\/bookbaaar.com\/products\/umbilical-cord-blood-banking-and-transplantation","provider":"Books Baar","version":"1.0","type":"link"}